<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489515</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000550095</org_study_id>
    <secondary_id>CCCWFU-99B98</secondary_id>
    <secondary_id>CCCWFU-BG99-047</secondary_id>
    <nct_id>NCT00489515</nct_id>
  </id_info>
  <brief_title>Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder</brief_title>
  <official_title>Visceral Lymphatic Mapping Project: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as visceral lymphatic mapping using isosulfan blue,
      may help find cancer of the pancreas, colon, stomach, small intestine, or gallbladder and
      find out how far the disease has spread.

      PURPOSE: This clinical trial is studying the side effects and how well visceral lymphatic
      mapping using isosulfan blue works in patients with cancer of the pancreas, colon, stomach,
      small intestine, or gallbladder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the safety and feasibility of visceral lymphatic mapping using isosulfan blue
           in patients with adenocarcinoma of the pancreas, colon, stomach, small bowel, or
           gallbladder.

        -  Evaluate the ability of surgically defined sentinel lymph nodes to predict whether other
           lymph nodes in the basin are involved with the tumor in these patients.

      Secondary

        -  Compare the results obtained from the sentinel lymph node (i.e., positive or negative
           for metastatic disease) with the results obtained from the other nodes in these
           patients.

        -  Compare immunohistochemical analysis with standard analysis of the sentinel lymph nodes
           in these patients.

        -  Evaluate the value of intraoperative touch prep analysis of sentinel lymph nodes in
           these patients.

      OUTLINE: This is a pilot study.

      During surgical resection of the primary tumor, patients receive isosulfan blue
      subcutaneously 5 minutes before undergoing sentinel lymph node identification/excision and
      radical lymphadenectomy. Tissue samples are analyzed by IHC for cytokeratins and CEA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, as determined by the number of adverse events resulting from procedure</measure>
    <time_frame>1 week</time_frame>
    <description>Safety will be assessed by documenting the number of adverse clinical events resulting from the procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">115</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <arm_group>
    <arm_group_label>patients with gastrointestinal cancer scheduled for surgery</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with gastrointestinal cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of adenocarcinoma of 1 of the following sites:

               -  Pancreas

               -  Stomach

               -  Colon

               -  Small bowel

               -  Gallbladder

          -  Patients with highly suspicious pancreatic lesions without definitive tissue biopsy
             are eligible

          -  No prior uncontrolled visceral malignancy

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No medical comorbidities that would preclude definitive resection

          -  No known allergies to isosulfan blue

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A. Levine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hundley JC, Shen P, Shiver SA, Geisinger KR, Levine EA. Lymphatic mapping for gastric adenocarcinoma. Am Surg. 2002 Nov;68(11):931-5.</citation>
    <PMID>12455783</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine EA, Shen P, Shiver SA, Waters G, Brant A, Geisenger KR. Intraoperative imprint cytology for evaluation of sentinel lymph nodes from visceral malignancies. J Gastrointest Surg. 2003 Jul-Aug;7(5):687-91.</citation>
    <PMID>12850683</PMID>
  </results_reference>
  <results_reference>
    <citation>Waters GS, Geisinger KR, Garske DD, Loggie BW, Levine EA. Sentinel lymph node mapping for carcinoma of the colon: a pilot study. Am Surg. 2000 Oct;66(10):943-5; discussion 945-6.</citation>
    <PMID>11261621</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomas KA, Lechner J, Shen P, Waters GS, Geisinger KR, Levine EA. Use of sentinel node mapping for cancer of the colon: 'to map or not to map&quot;. Am Surg. 2006 Jul;72(7):606-11; discussion 611-2.</citation>
    <PMID>16875082</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the gallbladder</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I gastric cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>localized gallbladder cancer</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

